Jimlig 100 Capsule contains Itraconazole 100 mg, an antifungal agent belonging to the triazole class, indicated for the treatment of a variety of systemic and superficial fungal infections. Itraconazole exerts its therapeutic effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for ergosterol synthesis, a critical component of fungal cell membranes. This disruption results in increased membrane permeability and ultimately fungal cell death. Jimlig 100 Capsule is prescribed for conditions such as aspergillosis, histoplasmosis, blastomycosis, onychomycosis, and other dermatophytic infections resistant to conventional therapy. The medication is administered orally, with absorption enhanced when taken with food. It is important to adhere to the prescribed dosage and duration to ensure efficacy and reduce the risk of resistance. Caution is advised in patients with hepatic impairment or congestive heart failure, as itraconazole may exacerbate these conditions. Potential adverse effects include gastrointestinal disturbances, headache, rash, and elevated liver enzymes. Drug interactions are significant due to itraconazole’s inhibition of CYP3A4; concomitant use with certain medications may require dose adjustments or monitoring. Regular liver function tests and clinical monitoring are recommended during therapy to ensure safety and therapeutic success.